Clinical Trial Detail

NCT ID NCT04243616
Title Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Medical College of Wisconsin
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel

Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST